ArticlePloS one2015
Beta-Lactamase Repressor BlaI Modulates Staphylococcus aureus Cathelicidin Antimicrobial Peptide Resistance and Virulence.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Nanoemulsification Promotes Antibacterial Activity of Selected Essential Oils Against Multidrug-Resistant Staphylococcus aureus Biofilms In Vitro.MicrobiologyOpen · 2026Article
- Isolation of a Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Article
- Enhanced Killing of Methicillin-Resistant Staphylococcus aureus With Ceftaroline or Vancomycin in Combination With Carbapenems.The Journal of infectious diseases · 2025Article
- Bibliometric analysis of hotspots inFrontiers in microbiology · 2025Article
- Insights into Kinases of ESKAPE Pathogens for Therapeutic Interventions.Cardiovascular & hematological agents in medicinal chemistry · 2024Review
- Antibiotic Resistance Genes, Virulence Factors, and Biofilm Formation in Coagulase-NegativePathogens (Basel, Switzerland) · 2023Article
- Prevalence and Characteristics of InvasiveMicroorganisms · 2023Article
- Pleiotropic Regulator GssR Positively Regulates Autotrophic Growth of Gas-FermentingMicroorganisms · 2023Article
- 2-Octylcyclopentanone Inhibits Beta Lactam Resistant Diabetic Wound Pathogens.Tropical life sciences research · 2023Article
- Progress in the Prevalence, Classification and Drug Resistance Mechanisms of Methicillin-ResistantInfection and drug resistance · 2023Review
- Genotypic and Phenotypic Characterization of SomeInfection and drug resistance · 2023Article
- Vancomycin Resistance inMicroorganisms · 2022Review
- Staphylococcus aureus lineages associated with a free-ranging population of the fruit bat Pteropus livingstonii retained over 25 years in captivity.Scientific reports · 2022Article
- The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent.Antibiotics (Basel, Switzerland) · 2021Review
- β-Lactams against the Fortress of the Gram-PositiveChemical reviews · 2021Review
- A protease-mediated mechanism regulates the cytochromeProceedings of the National Academy of Sciences of the United States of America · 2021Article
- AnMicrobial genomics · 2019Article
- A Livestock-Associated, Multidrug-Resistant, Methicillin-Resistant Staphylococcus aureus Clonal Complex 97 Lineage Spreading in Dairy Cattle and Pigs in Italy.Applied and environmental microbiology · 2016Article
- Evaluating the ototoxicity of an anti-MRSA peptide KR-12-a2.Brazilian journal of otorhinolaryngologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
BlaI is a repressor of BlaZ, the beta-lactamase responsible for penicillin resistance in Staphylococcus aureus. Through screening a transposon library in S. aureus Newman for susceptibility to cathelicidin antimicrobial peptide, we discovered BlaI as a novel cathelicidin resistance factor. Additionally, through integrational mutagenesis in S. aureus Newman and MRSA Sanger 252 strains, we confirmed the role of BlaI in resistance to human and murine cathelidicin and showed that it contributes to virulence in human whole blood and murine infection models. We further demonstrated that BlaI could be a target for innate immune-based antimicrobial therapies; by removing BlaI through subinhibitory concentrations of 6-aminopenicillanic acid, we were able to sensitize S. aureus to LL-37 killing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.